Brd2 Inhibits Adipogenesis via the ERK1/2 Signaling Pathway in 3T3-L1 Adipocytes

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Zang, Kun ^a   Wang, Jingyu ^a   Dong, Miaofang ^a   Sun, Ruixin ^a   Wang, Yuxiong ^a   Huang, Yinong ^a   Liu, Xiaoxia ^b   Li, Yimin ^b   Wang, Fangnian ^a,c   Yu, Min ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c IQUUM Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMODOMAIN CONTAINING PROTEIN 2; CCAAT ENHANCER BINDING PROTEIN ALPHA; DEXAMETHASONE; INSULIN; ISOBUTYLMETHYLXANTHINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UO 126; BRD2 PROTEIN, MOUSE; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, MOUSE; NONHISTONE PROTEIN;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL STRAIN 3T3; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; IMMUNOBLOTTING; INHIBITION KINETICS; MOUSE; NONHUMAN; PROADIPOCYTE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; 3T3 CELL LINE; ANIMAL; GENETICS; METABOLISM; PHYSIOLOGY;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ANIMALS; CCAAT-ENHANCER-BINDING PROTEINS; CHROMOSOMAL PROTEINS, NON-HISTONE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; IMMUNOBLOTTING; MAP KINASE SIGNALING SYSTEM; MICE; PPAR GAMMA;

EID: 84886044389     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078536     Document Type: Article

References (52)

1. Dorresteijn JA, Visseren FL, Spiering W, (2012) Mechanisms linking obesity to hypertension. Obes Rev 13: 17-26. doi:10.1111/j.1467-789X.2011.00914.x. PubMed: 21831233.
2. Franssen R, Monajemi H, Stroes ES, Kastelein JJ, (2011) Obesity and dyslipidemia. Med Clin North Am 95: 893-902. doi:10.1016/j.mcna.2011.06.003. PubMed: 21855698.
3. Rocha VZ, Libby P, (2009) Obesity, inflammation, and atherosclerosis. Nat. Rev Cardiol 6: 399-409. doi:10.1038/nrcardio.2009.55.
4. McCarthy MI, (2010) Genomics, type 2 diabetes, and obesity. N Engl J Med 363: 2339-2350. doi:10.1056/NEJMra0906948. PubMed: 21142536.
5. Speliotes EK, (2009) Genetics of common obesity and nonalcoholic fatty liver disease. Gastroenterology 136: 1492-1495. doi:10.1053/j.gastro.2009.03.020. PubMed: 19324104.
6. Pischon N, Heng N, Bernimoulin JP, Kleber BM, Willich SN, et al. (2007) Obesity, inflammation, and periodontal disease. J Dent Res 86: 400-409. doi:10.1177/154405910708600503. PubMed: 17452558.
7. Lloyd CM, Saglani S, (2013) Eosinophils in the Spotlight: Finding the link between obesity and asthma. Nat Med 19: 976-977. doi:10.1038/nm.3296. PubMed: 23921744.
8. Tzotzas T, Evangelou P, Kiortsis DN, (2011) Obesity, weight loss and conditional cardiovascular risk factors. Obes Rev 12: e282-e289. doi:10.1111/j.1467-789X.2010.00805.x. PubMed: 21054756.
9. Thompson D, Wolf AM, (2001) The medical-care cost burden of obesity. Obes Rev 2: 189-197. doi:10.1046/j.1467-789x.2001.00037.x. PubMed: 12120104.
10. Dalla Vecchia CF, Susin C, Rösing CK, Oppermann RV, Albandar JM, (2005) Overweight and obesity as risk indicators for periodontitis in adults. J Periodontol 76: 1721-1728. doi:10.1902/jop.2005.76.10.1721. PubMed: 16253094.
11. Zimmet P, Alberti KG, Shaw J, (2001) Global and societal implications of the diabetes epidemic. Nature 414: 782-787. doi:10.1038/414782a. PubMed: 11742409.
12. Bray GA, Tartaglia LA, (2000) Medicinal strategies in the treatment of obesity. Nature 404: 672-677. PubMed: 10766254.
13. Neel BA, Sargis RM, (2011) The paradox of progress: environmental disruption of metabolism and the diabetes epidemic. Diabetes 60: 1838-1848. doi:10.2337/db11-0153. PubMed: 21709279.
14. Gregoire FM, Smas CM, Sul HS, (1998) Understanding adipocyte differentiation. Physiol Rev 78: 783-809. PubMed: 9674695.
15. Rosen ED, Spiegelman BM, (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731-37734. PubMed: 11459852.
16. Burns KA, Vanden Heuvel JP, (2007) Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 1771: 952-960. doi:10.1016/j.bbalip.2007.04.018. PubMed: 17560826.
17. Hu E, Kim JB, Sarraf P, Spiegelman BM, (1996) Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274: 2100-2103. doi:10.1126/science.274.5295.2100. PubMed: 8953045.
18. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK, (1997) Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272: 5128-5132. doi:10.1074/jbc.272.8.5128. PubMed: 9030579.
19. Pagès G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, et al. (1993) Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A 90: 8319-8323. doi:10.1073/pnas.90.18.8319. PubMed: 8397401.
20. Graves JD, Campbell JS, Krebs EG, (1995) Protein serine/threonine kinases of the MAPK cascade. Ann N Y Acad Sci 766: 320-343. doi:10.1111/j.1749-6632.1995.tb26684.x. PubMed: 7486680.
21. Adams DG, Coffee RL Jr., Zhang H, Pelech S, Strack S, et al. (2005) Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes. J Biol Chem 280: 42644-42654. doi:10.1074/jbc.M502464200. PubMed: 16239230.
22. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, et al. (2002) A central role for JNK in obesity and insulin resistance. Nature 420: 333-336. doi:10.1038/nature01137. PubMed: 12447443.
23. Engelman JA, Berg AH, Lewis RY, Lin A, Lisanti MP, et al. (1999) Constitutively active mitogen-activated protein kinase kinase 6 (MKK6) or salicylate induces spontaneous 3T3-L1 adipogenesis. J Biol Chem 274: 35630-35638. doi:10.1074/jbc.274.50.35630. PubMed: 10585441.
24. Denis GV, Green MR, (1996) A novel, mitogen-activated nuclear kinase is related to a Drosophila developmental regulator. Genes Dev 10: 261-271. doi:10.1101/gad.10.3.261. PubMed: 8595877.
25. Denis GV, McComb ME, Faller DV, Sinha A, Romesser PB, et al. (2006) Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J Proteome Res 5: 502-511. doi:10.1021/pr050430u. PubMed: 16512664.
26. Guo N, Faller DV, Denis GV, (2000) Activation-induced nuclear translocation of RING3. J Cell Sci 113(17):: 3085-3091. PubMed: 10934046.
27. Wang F, Liu H, Blanton WP, Belkina A, Lebrasseur NK, et al. (2010) Brd2 disruption in mice causes severe obesity without Type 2 diabetes. Biochem J 425: 71-83. doi:10.1042/BJ20090928. PubMed: 19883376.
28. Floyd ZE, Stephens JM, (2002) Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J Biol Chem 277: 4062-4068. doi:10.1074/jbc.M108473200. PubMed: 11733495.
29. Florence B, Faller DV, (2001) You bet-cha: a novel family of transcriptional regulators. Front Biosci 6: D1008-D1018. doi:10.2741/Florence. PubMed: 11487468.
30. Beck S, Hanson I, Kelly A, Pappin DJ, Trowsdale J, (1992) A homologue of the Drosophila female sterile homeotic (fsh) gene in the class II region of the human MHC. DNA Seq 2: 203-210. PubMed: 1352711.
31. Dibenedetto AJ, Guinto JB, Ebert TD, Bee KJ, Schmidt MM, et al. (2008) Zebrafish brd2a and brd2b are paralogous members of the bromodomain-ET (BET) family of transcriptional coregulators that show structural and expression divergence. BMC Dev Biol 8: 39. doi:10.1186/1471-213X-8-39. PubMed: 18402692.
32. Denis GV, Vaziri C, Guo N, Faller DV, (2000) RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. Cell Growth Differ 11: 417-424. PubMed: 10965846.
33. Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K, (2003) The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci U S A 100: 8758-8763. doi:10.1073/pnas.1433065100. PubMed: 12840145.
34. Kanno T, Kanno Y, Siegel RM, Jang MK, Lenardo MJ, et al. (2004) Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol Cell 13: 33-43. doi:10.1016/S1097-2765(03)00482-9. PubMed: 14731392.
35. Denis GV, (2010) Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. Discov Med 10: 489-499. PubMed: 21189220.
36. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, et al. (1999) PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4: 611-617. doi:10.1016/S1097-2765(00)80211-7. PubMed: 10549292.
37. Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, et al. (1999) Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 3: 151-158. doi:10.1016/S1097-2765(00)80306-8. PubMed: 10078198.
38. Rommel C, Clarke BA, Zimmermann S, Nuñez L, Rossman R, et al. (1999) Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286: 1738-1741. doi:10.1126/science.286.5445.1738. PubMed: 10576741.
39. Ueda Y, Hirai Si, Osada Si, Suzuki A, Mizuno K, et al. (1996) Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem 271: 23512-23519. doi:10.1074/jbc.271.38.23512. PubMed: 8798560.
40. Jaiswal RK, Jaiswal N, Bruder SP, Mbalaviele G, Marshak DR, et al. (2000) Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase. J Biol Chem 275: 9645-9652. doi:10.1074/jbc.275.13.9645. PubMed: 10734116.
41. Schlesinger TK, Fanger GR, Yujiri T, Johnson GL, (1998) The TAO of MEKK. Front Biosci 3: D1181-D1186. PubMed: 9820741.
42. Zhang B, Berger J, Zhou G, Elbrecht A, Biswas S, et al. (1996) Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 271: 31771-31774. doi:10.1074/jbc.271.50.31771. PubMed: 8943212.
43. Tontonoz P, Hu E, Spiegelman BM, (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79: 1147-1156. doi:10.1016/0092-8674(94)90006-X. PubMed: 8001151.
44. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917. doi:10.1016/j.cell.2011.08.017. PubMed: 21889194.
45. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, et al. (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 108: 16669-16674. doi:10.1073/pnas.1108190108. PubMed: 21949397.
46. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, et al. (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528. doi:10.1038/nature10334. PubMed: 21814200.
47. Roux PP, Blenis J, (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320-344. doi:10.1128/MMBR.68.2.320-344.2004. PubMed: 15187187.
48. Baccarini M, (2005) Second nature: biological functions of the Raf-1 "kinase". FEBS Lett 579: 3271-3277. doi:10.1016/j.febslet.2005.03.024. PubMed: 15943972.
49. Meloche S, Pouysségur J, (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26: 3227-3239. doi:10.1038/sj.onc.1210414. PubMed: 17496918.
50. Roberts PJ, Der CJ, (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310. doi:10.1038/sj.onc.1210422. PubMed: 17496923.
51. Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, et al. (2010) EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 70: 8822-8831. doi:10.1158/0008-5472.CAN-10-0638. PubMed: 20978205.
52. Rauch J, Moran-Jones K, Albrecht V, Schwarzl T, Hunter K, et al. (2011) c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway. Cancer Res 71: 4664-4674. doi:10.1158/1538-7445.AM2011-4664. PubMed: 21512137.